VERTEX PHARMACEUTICALS INCORPORATED Vertex Pharmaceuticals Incorporated Stock
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 424.9 USD | -1.17% |
|
+4.16% | +5.02% |
| 11:53am | Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 | MT |
| 05-10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 10.75B 14.66B | Sales 2025 * | 11.67B 15.92B | Capitalization | 111B 151B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.99B 5.44B | Net income 2025 * | 4.46B 6.09B | EV / Sales 2024 * | 9.02 x |
| Net cash position 2024 * | 13.97B 19.06B | Net cash position 2025 * | 19.01B 25.93B | EV / Sales 2025 * | 7.88 x |
| P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
25.1
x | Employees | 5,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | -1.17% | ||
| 1 week | +4.16% | ||
| Current month | +8.78% | ||
| 1 month | +7.54% | ||
| 3 months | +2.26% | ||
| 6 months | +15.51% | ||
| Current year | +5.02% |
1 week
412.12
430.52
1 month
391.01430.52
Current year
391.01448.40
1 year
320.01448.40
3 years
176.36448.40
5 years
164.96448.40
10 years
63.60448.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 19-04-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.67% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 427.1 | -0.65% | 47 436 |
| 24-05-13 | 429.9 | +1.69% | 939,753 |
| 24-05-10 | 422.8 | +0.90% | 1,064,604 |
| 24-05-09 | 419 | +0.04% | 676,185 |
| 24-05-08 | 418.8 | +2.09% | 1,651,673 |
Delayed Quote Nasdaq, May 14, 2024 at 09:48 am
More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-05-15
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
429.9
USD
Average target price
462.6
USD
Spread / Average Target
+7.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.02% | 111B | |
| +10.90% | 105B | |
| -12.35% | 22.34B | |
| -2.91% | 21.93B | |
| -5.75% | 18.59B | |
| -36.52% | 18.12B | |
| -9.51% | 16.96B | |
| +3.64% | 13.7B | |
| +37.05% | 12.45B | |
| +295.86% | 7.98B |
- Stock Market
- Equities
- VRTX Stock
